GPBA receptor (TGR5) partial agonist (EC50
= 2.25 μ
M; 72% efficacy). Displays no activity at FXR. Also inhibits protein phosphate 1B (PTP1B) and glycogen phosphorylase. Suppresses cell proliferation and increases apoptosis in T24 bladder cancer cells. Antidiabetic, antihyperglycaemic, antitumor and hepatoprotective.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes.
Genet et al.
Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling.
Mu et al.
Biochemical basis of the antidiabetic activity of oleanolic acid and related pentacyclic triterpenes.
Castellano et al.